[Arterial hypertension. IV].
D018663:Adrenergic Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000378:metabolism / Q000627:therapeutic use; D001521:Behavior Therapy; D001682:Biological Availability; D005730:Ganglionic Blockers / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D007700:Kinetics; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D012083:Renin / Q000097:blood; D013565:Sympatholytics / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use
D018663:Adrenergic Agents; D000319:Adrenergic beta-Antagonists; D005730:Ganglionic Blockers; D008996:Monoamine Oxidase Inhibitors; D013565:Sympatholytics; D012083:Renin
Ipertensione arteriosa. Parte IV.